Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

被引:0
作者
Yuqin Song
Hui Zhou
Huilai Zhang
Wei Liu
Yuerong Shuang
Keshu Zhou
Fangfang Lv
Hao Xu
Jianfeng Zhou
Wei Li
Huaqing Wang
Hongyu Zhang
Haiwen Huang
Qingyuan Zhang
Wei Xu
Zheng Ge
Ying Xiang
Shuye Wang
Da Gao
Shun’e Yang
Jinying Lin
Lin Wang
Liqun Zou
Meifang Zheng
Jing Liu
Zonghong Shao
Ying Pang
Ruixiang Xia
Zhendong Chen
Ming Hou
Hongxia Yao
Ru Feng
Zhen Cai
Mingzhi Zhang
Wenhua Ran
Lin Liu
Shan Zeng
Wei Yang
Peng Liu
Aibin Liang
Xuelan Zuo
Qingfeng Zou
Junxun Ma
Wei Sang
Ye Guo
Wei Zhang
Yongqing Cao
Yan Li
Jifeng Feng
Xin Du
机构
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital
[2] Peking University Cancer Hospital and Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma
[3] Hunan Province Cancer Hospital,Department of Lymphoma and Hematology
[4] Tianjin Cancer Hospital,Department of Lymphoma
[5] Jiangxi Province Cancer Hospital,Cancer Chemotherapy Center
[6] The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,Hematology Department
[7] Fudan University Cancer Hospital,Oncology Department
[8] Yancheng City No. 1 People’s Hospital,Hematology Department
[9] Tongji Medical College Huazhong University of Science and Technology,Hematology Department
[10] The First Hospital of Jilin University,Hematology Department
[11] Tianjin City People’s Hospital,Oncology Department
[12] The Fifth Affiliated Hospital Sun Yat-Sen University,Oncology Department
[13] The First Affiliated Hospital of Soochow University,Department of Hematology
[14] Affiliated Cancer Hospital of Harbin Medical University,Department of Oncology
[15] Jiangsu Province Hospital,Hematology Department
[16] Zhongda Hospital Southeast,Hematology Department
[17] Chongqing Cancer Hospital,Department of Hematology and Oncology
[18] First Affiliated Hospital of Harbin Medical University,Hematology Department
[19] Affiliated Hospital of Inner Mongolia Medical University,Hematology Department
[20] First Affiliated Hospital of Xinjiang Medical University,Department of Lymphoma and Breast Cancer
[21] People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Hematological Rheumatology
[22] Hainan General Hospital,Oncology Department
[23] West China Hospital Sichuan University,Department of Oncology
[24] Linyi Cancer Hospital,Department of Hematology
[25] Third Xiangya Hospital of Central South University,Hematology Department
[26] General Hospital,Hematology Department
[27] Tianjin Medical University,Hematology Department
[28] Second Affiliated Hospital of Guangzhou Medical University,Hematology Department
[29] First Affiliated Hospital of Anhui Medical University,Oncology Department
[30] Second Affiliated Hospital of Anhui Medical University,Hematology Department
[31] Qilu Hospital of Shandong University,Hematology Department
[32] Hainan General Hospital,Hematology Department
[33] Nanfang Hospital,Department of Hematology
[34] First Affiliated Hospital of Zhejiang Medical University,Oncology Department
[35] First Affiliated Hospital of Zhengzhou Medical University,Cancer Center
[36] Chongqing Three-Gorge Central Hospital,Hematology Department
[37] First Affiliated Hospital of Chongqing Medical University,Oncology Department
[38] Xiangya Hospital Central South University,Hematology Department
[39] Shengjing Hospital of China Medical University,Hematology Department
[40] Affiliated Zhongshan Hospital of Fudan University,Hematology Department
[41] Tongji Hospital of Tongji University,Hematology Department
[42] Zhongnan Hospital of Wuhan,Department of Oncology
[43] Affiliated Cancer Hospital of Guangzhou Medical University,Department of Oncology
[44] Chinese PLA General Hospital,Department of Hematology
[45] Affiliated Hospital of Xuzhou Medical University,Oncology Department
[46] Shanghai East Hospital,Hematology Department
[47] Peking Union Medical College Hospital,Department of Hematology and Oncology
[48] First Hospital of Changsha,Hematology Department
[49] First Affiliated Hospital of China Medical University,Oncology Department
[50] Jiangsu Cancer Hospital,Hematology Department
来源
Advances in Therapy | 2021年 / 38卷
关键词
Biosimilar; CHOP; DLBCL; IBI301; Rituximab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1889 / 1903
页数:14
相关论文
共 362 条
  • [1] Thieblemont C(2018)Optimizing initial therapy in DLBCL Best Pract Res Clin Haematol 31 199-208
  • [2] Bernard S(2019)The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma Curr Oncol Rep 21 44-73
  • [3] Meignan M(1999)Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 26 66-2273
  • [4] Molina T(2017)Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience Adv Ther 34 2232-2466
  • [5] Hu R(1994)Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 2457-534
  • [6] Winter A(1998)Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group Ann Oncol 9 527-3274
  • [7] Hill BT(1997)IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 3266-1001
  • [8] Grillo-Lopez AJ(1998)Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9 995-e605
  • [9] White CA(2014)Regulatory and clinical considerations for biosimilar oncology drugs Lancet Oncol 15 e594-16
  • [10] Varns C(2017)An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements Future Oncol 13 5-23s